Collect of Cord Blood From Subjects at Risk for Sickle Cell Disease, for the Purpose of Laboratory Research

The study consists in collecting umbilical cord blood cells from newborns at risk of sickle cell disease, to perform laboratory experiments aiming to characterize the cells with HbS/HbS mutation, to develop methods to prepare, to gene-modify and to preserve these cells.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sickle Cell Disease Anemia Anemia, Hemolytic Anemia, Hemolytic, Congenital Anemia, Sickle Cell Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemoglobinopathies

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

CHSF

Corbeil-Essonnes, 91106, France

About this study

Pregnant individuals carrying at least one HbS allele will be included in the study to collect the umbilical cord blood of the child at birth. Collected cells will be used anonymously for genetic and bioexperimental laboratory research, aiming to develop autologous gene therapy for sickle cell disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Pregnant women, giving birth at CHSF and consenting to the collect and study of placental blood after delivery
Age 18 to 45 years
Biological testing of the participant includes hemoglobin electrophoresis and shows at least one HbS allele

Exclusion criteria

Lack of written consent
Minors (not 18 years old) or under guardianship
Diseases : HIV, Hepatitis B, Hepatitis C or HTLV (Human T Leukemia Virus).

Treatment and study plan

Primary outcomes

Number of samples with HbS/HbS genotype

Time frame: 3 years

Measured by DNA sequencing

Secondary outcomes

Number of samples with bio-experimental data

Time frame: 4 years

Consisting of cellular characterization, transduction and cell processing data

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Collaborators

Centre Hospitalier Sud Francilien

Registry information

Acronym: DREPACORD

Important dates

Study start: 2019
Primary completion: 2023
Study completion: 2023
First posted: Mar 15, 2019
Registry last updated: Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed